Neurizon Therapeutics Substantial Holder Mr Chek Loon Tan Lifts Stake to 8.02% via Placement on 9 November 2026

Aakashdeep

11 November 2026 12:32 PM AEDT

Neurizon Therapeutics Substantial Holder Mr Chek Loon Tan Lifts Stake to 8.02% via Placement on 9 November 2026

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Neurizon Therapeutics Limited (ASX:NUZ) has received a notice of change of interests of substantial holder from Mr Chek Loon Tan, disclosing that his voting power in the company increased from 6.34% to 8.02% following a series of acquisitions, with the most recent change recorded on 9 November 2026.

Key Points

Mr Chek Loon Tan's voting power in Neurizon Therapeutics increased from 6.34% (39,000,000 shares) to 8.02% (68,558,824 fully paid ordinary shares).
The most recent transaction, dated 9 November 2026, was a participation in a placement of 22,058,824 FPOs for consideration of $1,500,000.
Between the previous notice dated 7 January 2026 and the current notice, Mr Tan completed 19 separate transactions including on-market acquisitions and a placement shortfall participation.
Mr Chek Loon Tan is the registered holder of all 68,558,824 fully paid ordinary shares disclosed in the present notice.

Placement Participation on 9 November 2026

The most significant single transaction disclosed in the filing was Mr Chek Loon Tan's participation in a placement on 9 November 2026, through which he acquired 22,058,824 fully paid ordinary shares (FPOs) for consideration of $1,500,000. This transaction triggered the requirement to lodge the current substantial holder notice. The previous substantial holder notice had been given to the company on 7 January 2026, at which time Mr Tan held 39,000,000 FPOs representing a voting power of 6.34% in Neurizon Therapeutics Limited.

Series of On-Market Acquisitions Between April and September 2026

Prior to the November placement, Mr Tan completed a sequence of on-market acquisitions spanning April through September 2026. These transactions began with a placement of entitlement offer shortfall on 21 April 2026, involving 3,500,000 FPOs for $280,000. Subsequent on-market purchases were made on 14 May, 20 May, 22 May, 5 June, 9 June, 19 June, 23 June, 24 June, and 25 June 2026, as well as on 13 August, 20 August, 25 August, 26 August, 27 August, 28 August, 31 August, and 1 September 2026, with individual transaction considerations ranging from $762.32 to $26,890.81.

Present Relevant Interest in Neurizon Therapeutics

Following all disclosed transactions, Mr Chek Loon Tan holds a total of 68,558,824 fully paid ordinary shares in Neurizon Therapeutics Limited, representing a voting power of 8.02%. According to the filing, Mr Tan is both the registered holder and the person entitled to be registered as holder of all securities disclosed, with no associates identified. The notice was filed on 10 November 2026, with Mr Tan's address recorded as Reynolds Road, Mount Pleasant, WA 6153.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.